Lunit Inc. · KRX:328130
Lunit — Investor Presentation (October 2025)
28 slides from Lunit's investor presentation, October 2025
Slide 1: Conquer Cancer through AI
Conquer Cancer through Al © Lunit
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Lunit Inc. solely for information purposes. The information contained in this presentation has not been independently verified. No representation or warranty express or implied is made as to, and no reliance should be placed on, the fairness, accurac
Slide 3: Lunit and Volpara revenue 2019-2025.1H
41.7 28.5 21.9 Volpara 18.8 Lunit 19.3 19.8 0.2 1.1 10.7 9.7 5.1 2019 2020 2021 2022 2023 2024 2025.1H
Slide 4: Research publications and collaborations with leading institutions
• • • • • • • 1 Microsoft 5 Lunit 7 Google 1 Lunit 2 IBM 3 Microsoft 1 Lunit 2 Harvard Univ 3
Slide 5: Company Overview
Company Overview Conq uer Ca necer th rou g h Al | Increase cancer survival through Al-powered cancer diagnosis and treatment | © Lunit INsiGHT’ Cancer ail diagnosis ¥v Chest%Ray — Mammograpay support ‘ solutions + 5Oyx 50% more patients can Flagship (DBT) be screened earlier Lunit INSIGHT CXR { MMG
Slide 6: 2025 Investor Relations
2025 INVESTOR RELATIONS 2021 INVESTOR RELATIONS 6
Slide 7: Lunit INSIGHT Value: Higher Reading Accuracy
Lu Lunit INSIGHT Value Hig her Readin g Accu ra cy! Better performance than specialists, proven in major studies Extensively Clinically proven to show excellence in medical image analysis validated through studies +290 88 Studies/abstracts Chest eRay Lunit INSIGHT CXR Lunit INSIGHT CXR Dost Radiolog
Slide 8: INSIGHT Value: Real World Evidence
Lunit INSIGHT Value Lunit INSIGHT Real World Evidence! Building solid evidence through prospective studies Study Method What is prospective study? Study designed e Retrospective | Prospective Outcome is measured after the baseline state of the subjects is determined and controlled intervention apoli
Slide 9: INSIGHT Business: Current Commercialization Status
Lunit INSIGHT Business Current Commercialization Status = 6 First Al company collaboration for our x-ray busines§” (96) GE Healthcare “This is actually outtirst Al company collaboration for our x-ray business. The offering will be available on all of GE Number of paying sites worldwide digital, fixe
Slide 10: Competitive comparison by modality and publications
# of Modality Company (Country) Journals Lunit 64 Qure.ai 21 Annalise.ai 9 Chest X-Ray Oxipit 3 Zebra 0 Lunit Company A Company B Others (>10) None AI Algorithm A Algorithm B Lunit 58 Sensitivity 81.9% 67.0% 67.4% ScreenPoint 15 Mammography DeepHealth 2 Accuracy (ROC AUC) 95.6% 92.2% 92.0% Zebra 1 O
Slide 11: Lunit INSIGHT Strategy
INSIGHT Lunit INSIGHT Strategy Next Stepsecoming global standard of care by B2G expansion and successful reimbursement | Bto | National Cancer Screening Programs [GTilsieysaiits a Bie ponent aat (oe, ifteest1[3 Expansion inte Direct Sales First Case Europe Direct Sales Selected into Australia’s Nati
Slide 12: Lunit x Volpara
Lunit INSIGHT Lunit x Volpara Lunit Acquires Volpara Health (May, 2024) hy € Volpara HEALTH Density Reinforce Lung cancer screening Breast Risk Assessment Reinforce XX cancer screening 2000+ a . c Customers 9 [Dats 1s Lunit : Reporti jeinforce 4 0% + eporting Re US Market 7 © Lunit INSIGHT 36 Volpar
Slide 13: Strong Revenue Growth Driven by Lunit x Volpara Synergy
Lunit X Volpara Strong Revenue Growth Driven by Lunit x Volpara Synergy 39 27 22 19 14 8 17 9 2022 2023 2024 2025.1H 2025 INVESTOR RELATIONS 13
Slide 14: Direct to Patient Business Model: SecondRead AI
Lunit x Volpara Direct to Patient Business Model: SecondRead Al Gaining Strong Traction in US Market Traditional Business Model Image interpretation gq» Lunit INSIGHT DBT" oO: Patient Provider SecondReadAl” P New Business Model Provider offers SecondReadAl™ direct to patients for an out-of- pocket f
Slide 15: Cancer Screening: Data-AI Flywheel Ecosystem
Lunit Cancer Screening Customization Al for Autonomous Al Requires Platform Approach of Data-Al Flywheel Ecosystem Report we Biopsy result Radiclogy EMR ae Risk A A . Data-Al Flywheel Ecosystem | es a " Screening Center LEST eT EEE Community Hospital Laboratory Hospice Pre-visit Image Acquisition In
Slide 16: Our Future is Autonomous AI
Lunit Cancer Screening Our Future is Autonomous Al Pati Autonomous Al: Customization of Al Model for Each Customer Limitation of current Al applications : Single Al model for all customer ot Al v1.0 p> Abs ACC BO% Almodel Almodel B= Al v1.0 ams ACCB7% « Al v1.0 C int ACTO1% Data for core model train
Slide 17: IO uIHC
2025 INVESTOR RELATIONS IO uIHC 17
Slide 18: SCOPE Development: Personalized Approach Is Key to Cancer Treatment
Lunit SCOPE Development SCOPE Personalized Approach Is Key to Cancer Treatment igh Complexity in Cancer Even cancers in the same organ have different biological characteristics and prognoses. Morphological Type Mutation Type 1,000. 1,000. 10- ‘WHO's Morphological Classification Tumor Heterogeneity G
Slide 19: Lunit SCOPE: AI-powered Biomarkers for Major Cancer Drugs
Lunit SCOPE Development Lunit SCOPE: Al-powered Biomarkers for Major Cancer Drugs Cancer Treatment Landscape Targeted Therapy Immunotherapy 40% a t Immune Checkpoint Inhibitors Cancer Vaccines Adoptive Cell Therapy Cytokine Therapy \ Targeted Small Molecules 1 1 Antibody-Drug 1 Conjugates Global Rev
Slide 20: SCOPE Overview
Lunit SCOPE Overview Lunit SCOPE: Al-powered Biomarkers for Major Cancer Drugs Lumit SCOPE © Lunit SCOPE |o° Purpose Biomarkers for IO therapeutics Identification of predictive tissue/cell features Key Features (H&E) Potential CDx biomarkers for IO drugs Applications Complimentary biomarkers Related
Slide 21: External Validation set
External Validation set EGFR-mt 224 (28.3) 0.723 75.5% 52.6% TROP2 1243 / 3289 78.9% 94.0% KRAS-mt 130 (16.4) 0.721 86.2% 22.5% MET 3493 / 1134 80.5% 96.0% ALK-tr 46 (5.8) 0.738 39.1% 81.8% Claudin 18.2 2927 / 74 72.7% 94.0% ROS1-tr 62 (7.8) 0.609 14.5% 70.6% DLL3 2973 / 3 68.9% 100% RET-tr 11 (1.4)
Slide 22: SCOPE Business Model
Lunit SCOPE BM Business Model Paired with pharma’s drug, to generate high sales by active testing before treatment sos —_—_—_Q) am ) DrugDevelopmentProcess gy SEPT. «= STEP2 STEPS ; : Hospital > Scope test * If Positive 4 Giesaitine mg PEPER a y Patient Triage using : A Hy : ‘v) és A Lunit scope" :
Slide 23: Pharma customers and RUO revenue
1 Merck 11 Astellas 2 BMS 12 Incyte 3 Roche 13 Takeda RUO Revenue 4 J&J 14 Gliead $8,000,000 $7,000,000 5 AZ 15 Sanofi $6,000,000 $5,000,000 6 Novartis 16 BeiGene $4,000,000 $3,000,000 7 Pfizer 17 Daiichi $2,000,000 $1,000,000 8 Amgen 18 Bayer $- 9 Eli Lilly 19 GSK 10 Abbvie 20 Teva 2025 INVESTOR RE
Slide 24: Labcorp, Quest, Sonic, Neogenomics, Pathgroup
1 Labcorp 2 Quest 3 Sonic 4 Neogenomics 5 Pathgroup 2025 INVESTOR RELATIONS
Slide 25: Lunit SCOPE Next Steps
Lunit INSIGHT Lumit SCOPE Appendix Next Steps Cover All Types of Drugs Multi-omic Biomarkers Drug Discovery & Development Lunit SCOPE will be able to cover all Lunit SCOPE will deliver optimal cancer LunitSCOPE biomarkers shall be applied to types of oncology drugs treatment through multi-omics anal
Slide 26: Vision
Vision Conquer Cancer through Al-powered Precision Medicine Having strong faith that a data-driven approach is the future, Lunit will be the center of cancer care Globally become the new standard of care Personalized Screening / Diagnosis Personalized Treatment. 5. Precision ©. Precision o§ Precisio
Slide 27: Thank You
THANK YOU @Lunit
Slide 28: Appendix: Consolidated Financial Statements
Appendix Consolidated Financial Statements Statement of Financial Position UnitxRW milion 2003 2024 2023 2022 Current Asset 87,924 111,062 230,418 68,050 Non Current Asset 325,086. 324,215 37,503 29,103 Total Assets 413,010 435,277 267,921 97,153 Current Liabilities 253,601 262,736 12,794 9,446 Non